10th Dec 2014 07:00
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Appointment of Joint Broker
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, is pleased to announce the appointment of Hybridan LLP as joint broker with immediate effect.
OptiBiotix Health plc | www.optibiotix.com |
Stephen O'Hara, Chief Executive | Contact via Walbrook below |
Cairn Financial Advisers LLP Nominated Adviser |
Tel: 020 7148 7900 |
Liam Murray / Avi Robinson | |
Peterhouse Corporate Finance Ltd Joint Broker |
Tel: 020 7469 0936 |
Lucy Williams / Duncan Vasey | |
Hybridan LLP Joint Broker Claire Louise Noyce |
Tel: 020 3713 4581 |
Walbrook PR Ltd Financial PR |
Tel: 020 7933 8780 or [email protected] |
Anna Dunphy | Mob: 07876 741 001 |
Mike Wort | Mob: 07900 608 002 |
About OptiBiotix- www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
Related Shares:
OptiBiotix Health